Ginkgo Bioworks Inc. (NYSE:DNA) is up 6.68% intraday at $10.38 as Merck KGaA's $11.3 billion acquisition of Bio-Techne re-rates life-science platform companies broadly, lifting synthetic biology peers on M&A premium sentiment.
Key Highlights
• Ginkgo Bioworks is trading at $10.38, up 6.68% intraday, carried higher by sector-wide re-rating following Merck KGaA's $11.3 billion acquisition of Bio-Techne.
• Q1 2026 revenue was $19 million following the Biosecurity divestiture, with cash burn down roughly a sixth and $373 million cash on hand with no bank debt.
• A collaboration with OpenAI using GPT-5 targets a two-fifths reduction in protein synthesis costs; a partnership with Invaio Sciences extends the platform into agricultural microbial manufacturing.
• The 52-week range of $5.37 to $17.58 places today's $10.38 intraday level near the middle of the annual band.
M&A Catalyst Re-Rates Synthetic Biology Sector
Ginkgo Bioworks Inc. (NYSE:DNA), a Boston-based synthetic biology platform company providing cell-engineering services and autonomous lab infrastructure to pharmaceutical, agricultural, and industrial clients, is up 6.68% intraday at $10.38. Merck KGaA's announcement of an $11.3 billion acquisition of Bio-Techne has triggered a broad re-rating of life-science platform businesses, as the market applies an M&A premium to companies with proprietary biological infrastructure. Ginkgo, as the most visible pure-play synthetic biology platform globally, is a natural read-through beneficiary. No company-specific news was released today.
AI Integration and Platform Pivot
Ginkgo's 2026 strategy centres on two parallel pivots: autonomous lab infrastructure build-out and AI integration into cell-engineering workflows. A collaboration with OpenAI using GPT-5 targets a reduction in protein synthesis costs of approximately two-fifths, expanding the economics of the platform for pharmaceutical clients. A partnership with Invaio Sciences on agricultural microbial manufacturing diversifies revenue streams beyond pharmaceutical cell programming.
The autonomous lab pivot is the longer-term structural bet: replacing human technicians with robotic and AI-driven workflows to drive down the marginal cost of cell programming experiments, expanding the commercial addressable market.
Q1 2026 Financials: Leaner Balance Sheet
Ginkgo reported Q1 2026 revenue of $19 million following the divestiture of its Biosecurity business. Cash burn declined by roughly a sixth, and the company holds $373 million in cash with no bank debt, providing approximately two years of runway at the current burn rate. The clean balance sheet reduces dilution risk during the multi-year platform transformation.
The Bio-Techne acquisition has reignited M&A optionality discussions for platform biology companies. Ginkgo's proprietary cell-programming infrastructure and AI integration make it a credible strategic target, though the gap between M&A speculation and fundamental valuation remains wide given declining post-divestiture revenue.






Please wait processing your request...